I'm not an expert on this but doubt it would be an issue...

I'm not an expert on this but doubt it would be an issue regarding commercial discussions (noting commercial pilots are offered to prospective clients) nor suspect this would materially hold back the SP. From some high level research, I think we're not comparing apples and apples in regards to sample size, as there may be different sample size for new drug trials vs other types of clinical studies.

You would expect new drug clinical trials to require large/larger sample size by the FDA/other regulators, before approval is given.

Our product is not a new drug but rather a medical device and it is already FDA and TGA cleared. I believe we are simply building a trove of clinical data to formally demonstrate its usefulnesss to assist in commercialisation. The sample size would be selected by the expert academics (e.g. Uni of Miami) perhaps in conjunction with 4DX and would be no smaller or larger than necessary for the relevant purposes.

In the mean time, this is yet another opportunity to top up a great price, which I consider does not reflect the strides the company has made. I'm also guessing the SPP is already oversubscribed (even in the absence of today's VQ announcement)